Current status of gynecologic cancer in Japan

다국어 초록 (Multilingual Abstract)

To make an overview of the current status of gynecologic cancer in Japan, we reviewed the recent incidence of cervical, endometrial, and ovarian cancer in Japanese women. The incidence of all three cancers has increased, but trends differ respectively. In age specific cancer site distribution data, the uterus and ovary are leading sites of high incidence
among Japanese women younger than 40 years of age. Therefore, fertility sparing cancer treatment has received much attention. Several multicenter clinical trials have been done by Japanese groups, and some excellent evidence has been collected for endometrial and ovarian cancer. A promising international collaboration trial for ovarian clear cell carcinoma is also underway at the present time.

다국어 초록 (Multilingual Abstract)

To make an overview of the current status of gynecologic cancer in Japan, we reviewed the recent incidence of cervical, endometrial, and ovarian cancer in Japanese women. The incidence of all three cancers has increased, but trends differ respectively. In age specific cancer site distribution data, the uterus and ovary are leading sites of high incidence
among Japanese women younger than 40 years of age. Therefore, fertility sparing cancer treatment has received much attention. Several multicenter clinical trials have been done by Japanese groups, and some excellent evidence has been collected for endometrial and ovarian cancer. A promising international collaboration trial for ovarian clear cell carcinoma is also underway at the present time.

참고문헌 (Reference)

1 "Report from gynecologic tumor committee of JSOG" 59 : 952-, 2007

2 "Report from gynecologic tumor committee of JSOG" 61 : 936-, 2009

3 "Report from gynecologic tumor committee of JSOG" 52 : 855-, 2000

4 Susumu N, "Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate-and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study" 108 : 226-233, 2008

5 Isonishi S, "Randomized phase III trial of conventional paclitaxel and carboplatin (c-TC) versus dose dense weekly paclitaxel and carboplatin (dd-TC) in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: Japanese Gynecologic Oncology [abstract]" 26 (26): 2008

6 Japan Society of Gynecologic Oncology, "Ovarian cancer treatment guidelines 2007" Kanehara & Co. Ltd 2007

7 Ushijima K, "Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women" 25 : 2798-2803, 2007

8 Enomoto T, "Is clear cell carcinoma and mucinous carcinoma of the ovary sensitive to combination chemotherapy with paclitaxel and carboplatin? [abstract]" 22 : 2003

9 Sugiyama T, "Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer" 128 : 211-218, 1998

10 Kaku T, "Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome" 167 : 39-48, 2001

11 Taguchi K, "Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy" 88 : 2584-2589, 2000

12 Oshima A, "Cancer statistic statement" Shinohara Publishing 2004

13 Takano M, "Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary" 16 : 1301-1306, 2006

14 Rose PG, "A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma" 96 : 296-300, 2005